Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571619 · ClinicalTrials.gov registry record · Phase 2
HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 643
- Enrollment target
NCT04571619: Completed Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT04571619 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 643 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (383% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04571619, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 643 participants
- Enrollment target
Study Summary
HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid use, and that buprenorphine will be acceptable and tolerable as an approach to managing physical dependence on opioids in this patient population.
Primary Outcome
Pain interference as measured by the Brief Pain Index (BPI) Interference Scale. This is typically scored as the mean of the seven items. Lowest score - 0; Highest score - 10. A higher score is worse.
Interventions
- DRUG Buprenorphine
- BEHAVIORAL Pain Coping Skills Training (PCST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2021-01-03 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 2 |
What the finished NCT04571619 record still lists
NCT04571619 is an interventional study that assigns participants to a tested intervention. The registered 643 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (383% higher).
The record links to 0 conditions, and to 2 interventions - of which Buprenorphine is the first listed.
NCT04571619 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04571619 about?
NCT04571619 is a clinical study titled "HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis". HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid ...
What is the current status of trial NCT04571619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 643 participants. The study started on 2021-01-03. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT04571619?
The interventions under investigation include: Buprenorphine (DRUG), Pain Coping Skills Training (PCST) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04571619?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04571619's enrollment target sits among peer trials
643 50th of 2000 higher than 1,951 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI